Hostname: page-component-7479d7b7d-jwnkl Total loading time: 0 Render date: 2024-07-11T06:28:32.508Z Has data issue: false hasContentIssue false
  • English
  • Français

The lessons of platelet monoamine oxidase1

Published online by Cambridge University Press:  09 July 2009

R. H. Belmaker
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Psychological Medicine , Volume 14 , Issue 2 , May 1984 , pp. 249 - 253
Copyright
Copyright © Cambridge University Press 1984

References

Baron, M., Levitt, M., Asnis, L. & Fein, M. (1983). Prolactin levels in schizophrenia: relation to platelet monoamine oxidase, plasma amine oxidase, plasma dopamine-β-hydroxylase, and erythrocyte catechol-O-methyltransferase activity. Biological Psychiatry 18, 579–582.Google Scholar
Belmaker, R. H., Ebstein, R. P., Ebbesen, K. & Rimon, R. (1976 a). Platelet monoamine oxidase in schizophrenic and manic-depressive illness. British Journal of Psychiatry 129, 227–232.CrossRefGoogle ScholarPubMed
Belmaker, R. H., Ebstein, R. P., Rimon, R., Wyatt, R. J. & Murphy, D. L. (1976 b). Electrophoresis of platelet monoamine oxidase in schizophrenia and manic-depressive illness. Acta Psychiatrica Scandinavica 54, 67–72.CrossRefGoogle ScholarPubMed
Belmaker, R. H., Galon, A., Perez, L. & Ebstein, R. P. (1977 a). Platelet MAO in schizophrenics with and without family history of schizophrenia. British Journal of Psychiatry 131, 551–552.CrossRefGoogle ScholarPubMed
Belmaker, R. H., Reches, A. & Ebstein, R. P. (1977 b). Km of platelet monoamine oxidase in schizophrenia. Lancet ii, 821.Google Scholar
Belmaker, R. H., Bracha, H. & Ebstein, R. P. (1980). Platelet MAO in affective disorder and alcoholism. Schizophrenia Bulletin 6, 320–323.CrossRefGoogle ScholarPubMed
Berrettini, W. H. & Vogel, W. H. (1978). Evidence for an endogenous inhibitor of platelet MAO in chronic schizophrenia. American Journal of Psychiatry 135, 605–607.Google Scholar
Buchsbaum, M. S. & Rieder, R. O. (1979). Biologic heterogeneity and psychiatric research. Archives of General Psychiatry 36, 1163–1169.Google Scholar
Buchsbaum, M. S., Coursey, R. D. & Murphy, D. L. (1976). The biochemical high risk paradigm: behavioral and familial correlates of low platelet monoamine oxidase activity. Science 194, 339–341.CrossRefGoogle ScholarPubMed
Carlsson, A., Persson, T., Roos, B. E. & Wålinder, J. (1972). Potentiation of phenothiazines by α-methyl-tyrosine in treatment of chronic schizophrenia. Journal of Neural Transmission 33, 83–90.CrossRefGoogle Scholar
Chojnacki, M., Kralik, P., Allen, R. H., Ho, B. T., Schoolar, J. C. & Smith, R. C. (1981). Neuroleptic-induced decrease in platelet MAO activity of schizophrenic patients. American Journal of Psychiatry 138, 838–840.Google ScholarPubMed
Crow, T. J., Baker, H. F., Cross, A. J., Joseph, M. H., Lofthouse, R., Longden, A., Owen, F., Riley, G. J., Glover, V. & Killpack, W. S. (1979). Monoamine mechanisms in chronic schizophrenia: postmortem neurochemical findings. British Journal of Psychiatry 134, 249–256.CrossRefGoogle ScholarPubMed
De Lisi, L. E., Wise, C. D., Bridge, T. P., Rosenblatt, J. E., Wagner, R. L., Morihisa, J., Karson, C., Potkin, S. G. & Wyatt, R. J. (1981). A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients. Psychiatry Research 4, 95–107.Google Scholar
Eckert, B., Gottfries, C. G., Von Knorring, L., Oreland, L., Wiberg, A. & Winblad, B. (1980). Brain and platelet monoamine oxidase in mental disorders. I. Schizophrenics and cycloid psychotics. Progress in Neuropsychopharmacology 4, 57–68.Google ScholarPubMed
Fowler, C. J., Wiberg, A., Oreland, L., Marcusson, J. & Winblad, B. (1980). The effect of age on the activity and molecular properties of human brain monoamine oxidase. Journal of Neural Transmission 49, 1–20.Google Scholar
Friedhoff, A. J. & Van Winkle, E. (1962). Isolation and characterization of a compound from urine of schizophrenics. Nature 194, 897–898.Google Scholar
Gershon, E. S., Belmaker, R. H., Ebstein, R. P. & Jonas, W. Z. (1977). Plasma monoamine oxidase activity unrelated to genetic vulnerability to primary affective illness. Archives of General Psychiatry 34, 731–734.Google Scholar
Heath, R. G., Martens, S., Leach, B. E., Cohen, M. & Feigley, C. A. (1958). Behavioral changes in nonpsychotic volunteers following the administration of taraxein, the substance obtained from serum of schizophrenic patients. American Journal of Psychiatry 114, 917.CrossRefGoogle ScholarPubMed
Kleinman, J. E., Potkin, S. G., Rogol, A., Buchsbaum, M. S., Gillin, J. C., Murphy, D. L., Nasrallah, H. E. & Wyatt, R. J. (1979). A correlation between platelet monoamine oxidase activity and plasma prolactin concentrations in man. Science 206, 479–481.CrossRefGoogle ScholarPubMed
Kobes, R. D., Potkin, S. G., Wise, C. D., Bridge, T. P., Neckers, L. M. & Wyatt, R. J. (1979). Some kinetic parameters of platelet monoamine oxidase in chronic schizophrenia. Psychiatry Research 1, 179–185.Google Scholar
McEwen, C. M. Jr (1972). The soluble monoamine oxidase of human plasma and sera. In Monoamine Oxidases – New Vistas (ed. Costa, E. and Sandler, M.), pp. 151–165. Raven Press: New York.Google Scholar
Meltzer, H. Y. (1968). Creatinine kinase and aldolase in serum: abnormality common to acute psychoses. Science 159, 1368–1370.CrossRefGoogle Scholar
Meltzer, H. Y. & Stahl, S. M. (1974). Platelet monoamine oxidase activity and substrate preferences in schizophrenic patients. Research Communications in Chemical Pathology and Pharmacology 7, 419–431.Google ScholarPubMed
Murphy, D. L. & Kalin, N. H. (1980). Biological and behavioral consequences of alterations in monoamine oxidase activity. Schizophrenia Bulletin 6, 355–367.Google Scholar
Murphy, D. L. & Weiss, R. (1972). Reduced monoamine oxidase activity in blood platelets from bipolar depressed patients. American Journal of Psychiatry 128, 35–41.Google Scholar
Murphy, D. L. & Wyatt, R. J. (1972). Reduced platelet monoamine oxidase activity in chronic schizophrenia. Nature 238, 225–226.CrossRefGoogle Scholar
Murphy, D. L., Belmaker, R. H. & Wyatt, R. J. (1975). Monoamine oxidase in schizophrenia and other behavioural disorders. In Catecholamines and Their Enzymes in Relation to Neuropathology of Schizophrenia (ed. Kety, S. S. and Matthysse, S.), pp. 221–248. Pergamon Press: New York.Google Scholar
Murphy, D. L., Belmaker, R. H., Buchsbaum, M., Martin, N. F., Ciaranello, R. & Wyatt, R. J. (1977). Biogenic amine-related enzymes and personality variations in normals. Psychological Medicine 7, 149–157.Google Scholar
Nies, A.Robinson, D. S., Lamborn, K. R. & Lampert, R. P. (1973). Genetic control of platelet and plasma monoamine oxidase activity. Archives of General Psychiatry 28, 834–837.CrossRefGoogle ScholarPubMed
Owen, F., Bourne, R., Crow, T. J., Fadhli, A. A. & Johnstone, E. C. (1981). Platelet monoamine oxidase in schizophrenia. Archives of General Psychiatry 33, 1370–1373.CrossRefGoogle Scholar
Pollin, W. & Stabenau, J. R. (1968). Biological, psychological and historical differences in a series of monozygotic twins discordant for schizophrenia. In The Transmission of Schizophrenia (ed. Rosenthal, D. and Kety, S. S.), pp. 317–332. Pergamon Press: London.Google Scholar
Propping, P., Rey, E. R. & Beckmann, H. (1981). Platelet monoamine oxidase in healthy subjects: The ‘biochemical high-risk paradigm’ revisited. Archiv für Psychiatrie und Nervenkrankheiten 955, 1–11.Google Scholar
Reches, A., Ebstein, R. P. & Belmaker, R. H. (1977). d-Amphetamine inhibition of platelet MAO in schizophrenia. Biological Psychiatry 12, 655–660.Google Scholar
Rosenthal, D. (1970). Genetic Theory and Abnormal Behavior. McGraw-Hill: New York.Google Scholar
Rosenthal, D., Wender, P. H. & Kety, S. S. (1971). The adopted-away offspring of schizophrenics. American Journal of Psychiatry 128, 307–311.Google Scholar
Sahai, S., Arora, R. & Meltzer, H. Y. (1981). Effect of chlorpromazine treatment on monoamine oxidase activity in platelets isolated by the Corash method. Psychiatry Research 5, 111–114.CrossRefGoogle ScholarPubMed
Schwartz, M. A., Wyatt, R. J., Yang, H. Y. T. & Neff, N. H. (1974). Multiple forms of brain monoamine oxidase in schizophrenic and normal individuals. Archives of General Psychiatry 31, 557–560.CrossRefGoogle ScholarPubMed
Shaskan, E. G., Peszke, M. A. & Niederman, J. C. (1980). Studies of platelet monoamine oxidase activity in Epstein-Barr and dengue virus infections. Schizophrenia Bulletin 6, 347–354.CrossRefGoogle ScholarPubMed
Snyder, S. H., Taylor, K. M., Coyle, J. & Meyerhoff, J. L. (1970). The role of brain dopamine in behavioural regulation and the actions of psychotropic drugs. American Journal of Psychiatry 127, 199–207.Google Scholar
Watson, J. D. (1965). Molecular Biology of the Gene. W. A. Benjamin: New York.Google Scholar
Wise, C. D., Potkin, S., Bridge, P. & Wyatt, R. J. (1979). An endogenous inhibitor of platelet MAO activity in chronic schizophrenia. Failure to replicate. American Journal of Psychiatry 136, 1336–1337.Google ScholarPubMed
Wyatt, R. J., Murphy, D. L., Belmaker, R. H., Cohen, S., Donnelly, O. H. & Pollin, W. (1974). Reduced monoamine oxidase activity in platelets: A possible genetic marker for vulnerability to schizophrenia. Science 173, 916–918.Google Scholar
Wyatt, R. J., Belmaker, R. H. & Murphy, D. L. (1975). Low platelet monoamine oxidase and vulnerability to schizophrenia. In Genetics and Psychopharmacology (ed. Mendlewicz, J.), pp. 38–56. S. Karger: Basle.Google Scholar
Wyatt, R. J., Potkin, S. G., Bridge, T. P., Phelps, B. H. & Wise, C. D. (1980). Monoamine oxidase in schizophrenia: An overview. Schizophrenia Bulletin 6, 199–207.CrossRefGoogle ScholarPubMed
Zuckerman, M. (1978). Sensation seeking. In Dimensions of Personality (ed. London, E.), pp. 487–559. Wiley & Sons: New York.Google Scholar